Efficacy and Safety of Methylprednisolone for Lung Surgery: a Systematic Review and Meta-analysis of Randomized Controlled Trials

Xi Fu,Xin Ye,Li-Na An,Hua Jiang,Wen-Bo Huang,Ya Huang,Jing Dong,Yi-Feng Ren
DOI: https://doi.org/10.1007/s40122-022-00443-4
IF: 3.96
2022-10-19
Pain and Therapy
Abstract:IntroductionThe administration of methylprednisolone (MP) is a component of perioperative multimodal analgesia that mitigates the potentially deleterious effects of postoperative pain and opioid consumption. However, a systematic evaluation of the efficacy and safety of MP is lacking. The present systematic review and meta-analysis was performed to quantify the potential clinical benefits and risks of perioperative MP in lung surgery.MethodsWe searched seven electronic databases for randomized controlled trials (RCTs) comparing MP with placebo. Coprimary outcomes were rest pain scores, dynamic pain scores, and cumulative morphine equivalent consumption within 24 h postoperatively.ResultsA total of 11 trials including 643 participants were selected for our meta-analysis. The results demonstrated that the MP group had a significant difference in coprimary outcomes (rest pain scores, dynamic pain scores, and cumulative morphine equivalent consumption) compared with the placebo group; nevertheless, the improvement was not clinically meaningful based on minimum clinically important differences (MCID). Notably, MP administration reduced serum levels of interleukin (IL)-6 at 6 h (weighted mean difference −20.49 pg/mL; 95% CI −29.94 to −11.04), and decreased the incidence rate of acute lung injury (rate ratio 0.18; 95% CI 0.03–0.98) and cognitive dysfunction (rate ratio 0.43; 95% CI 0.21–0.88) compared with the placebo group.ConclusionsOur findings suggest that the administration of MP contributed to an insignificant relief in acute postoperative pain for lung surgery in a clinical setting. Future studies should focus on exploring the role of MP in reducing pulmonary and surgical-related complications after lung surgery.Clinical Trial NumberPROSPERO registration number CRD42022314224.
clinical neurology
What problem does this paper attempt to address?